Arch Therapeutics, Inc. has appointed James Sulat to its board of directors as an independent member, effective August 19, 2015. Mr. Sulat served as chief executive officer and chief financial officer of Maxygen Inc. from October 2009 to June 2013. Prior to this, he was chief executive officer, chief financial officer and a member of the board of directors at Memory Pharmaceuticals Corp.

from 2005 to 2008. He previously served in senior executive roles for R.R. Donnelley & Sons Co., Chiron Corporation, Stanford Health Services, Inc., and Esprit de Corp, Inc. He currently serves as chairman of the board of directors of Momenta Pharmaceuticals, Inc. He has additionally served on numerous boards including Valneva SE, AMAG Pharmaceuticals, Inc., diaDexus, Inc., and General Surgical Innovations, Inc.